ES2183836T3 - Nuevo agente para controlar la actividad celular. - Google Patents
Nuevo agente para controlar la actividad celular.Info
- Publication number
- ES2183836T3 ES2183836T3 ES94909262T ES94909262T ES2183836T3 ES 2183836 T3 ES2183836 T3 ES 2183836T3 ES 94909262 T ES94909262 T ES 94909262T ES 94909262 T ES94909262 T ES 94909262T ES 2183836 T3 ES2183836 T3 ES 2183836T3
- Authority
- ES
- Spain
- Prior art keywords
- dominant
- agent
- control
- cell
- cellular activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939305735A GB9305735D0 (en) | 1993-03-19 | 1993-03-19 | Novel agent for controlling cell activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2183836T3 true ES2183836T3 (es) | 2003-04-01 |
Family
ID=10732382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94909262T Expired - Lifetime ES2183836T3 (es) | 1993-03-19 | 1994-03-18 | Nuevo agente para controlar la actividad celular. |
Country Status (24)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| ES2187200T3 (es) * | 1998-05-13 | 2003-05-16 | Biotecon Ges Fur Biotechnologi | Proteina hibrida para inhibir la desgranulacion de mastocitos y su uso. |
| GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| GB9926875D0 (en) * | 1999-11-12 | 2000-01-12 | Microbiological Research Agenc | Use of lytic toxins and toxin conjugates |
| GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| DE602004025781D1 (de) * | 2003-11-14 | 2010-04-15 | Starhome Gmbh | Steuerung von ankommenden Anrufen für Roamingteilnehmer eines zellularen Mobilfunknetzes |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| JP5728380B2 (ja) * | 2008-06-12 | 2015-06-03 | シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ | 神経内分泌疾患の抑制 |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| JP6601922B2 (ja) | 2015-01-09 | 2019-11-06 | イプセン バイオイノベーション リミテッド | 陽イオン性神経毒 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| JP7186228B2 (ja) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | 非細胞毒性プロテアーゼの注入を案内するための超音波の使用 |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| AU2021438810B2 (en) | 2021-03-30 | 2024-07-18 | Ipsen Biopharm Limited | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| US20250195626A1 (en) | 2021-03-30 | 2025-06-19 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| EP0329184A3 (en) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
| US5045451A (en) * | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
| WO1990010692A1 (en) * | 1989-03-15 | 1990-09-20 | University Of Florida | Monoclonal antibody for use in detection and treatment of childhood leukemia |
| US5300496A (en) * | 1991-09-30 | 1994-04-05 | The University Of British Columbia | Complexed vanadium for the treatment of diabetes mellitus |
| US5877295A (en) * | 1992-09-30 | 1999-03-02 | The Center For Blood Research | Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen |
-
1993
- 1993-03-19 GB GB939305735A patent/GB9305735D0/en active Pending
-
1994
- 1994-03-18 AT AT94909262T patent/ATE228856T1/de not_active IP Right Cessation
- 1994-03-18 PL PL94310698A patent/PL178895B1/pl unknown
- 1994-03-18 KR KR1019950703985A patent/KR960700756A/ko not_active Ceased
- 1994-03-18 SG SG1996007056A patent/SG73411A1/en unknown
- 1994-03-18 PT PT94909262T patent/PT689459E/pt unknown
- 1994-03-18 FI FI954390A patent/FI954390A7/fi unknown
- 1994-03-18 BR BR9406232A patent/BR9406232A/pt not_active Application Discontinuation
- 1994-03-18 JP JP52080694A patent/JP4300265B2/ja not_active Expired - Lifetime
- 1994-03-18 ES ES94909262T patent/ES2183836T3/es not_active Expired - Lifetime
- 1994-03-18 CN CNB941921255A patent/CN1195551C/zh not_active Expired - Fee Related
- 1994-03-18 NZ NZ262484A patent/NZ262484A/en unknown
- 1994-03-18 DK DK94909262T patent/DK0689459T3/da active
- 1994-03-18 HU HU9502673A patent/HU217220B/hu not_active IP Right Cessation
- 1994-03-18 EP EP94909262A patent/EP0689459B1/en not_active Expired - Lifetime
- 1994-03-18 AU AU62175/94A patent/AU671203C/en not_active Expired
- 1994-03-18 CA CA002158647A patent/CA2158647A1/en not_active Abandoned
- 1994-03-18 DE DE69431832T patent/DE69431832T2/de not_active Expired - Lifetime
- 1994-03-18 SK SK1155-95A patent/SK115595A3/sk unknown
- 1994-03-18 CZ CZ952426A patent/CZ242695A3/cs unknown
- 1994-03-20 IL IL10904594A patent/IL109045A0/xx unknown
- 1994-03-21 IN IN200MA1994 patent/IN178499B/en unknown
-
1995
- 1995-09-15 NO NO953643A patent/NO953643L/no not_active Application Discontinuation
-
2007
- 2007-06-28 US US11/819,647 patent/US20080070278A1/en not_active Abandoned
- 2007-08-15 JP JP2007211720A patent/JP4740206B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2183836T3 (es) | Nuevo agente para controlar la actividad celular. | |
| ES2163008T3 (es) | Procedimiento para la obtencion de preparados de principios activos en forma de una disolucion solida de principio activo en una matriz polimera, asi como preparados de principios activos obtenidos con este procedimiento. | |
| ATE375142T1 (de) | Medizinische aerosolformulierungen | |
| MX9300848A (es) | Composiciones de clindamicina y peroxido de benzoilo para tratamiento de acne. | |
| ES2115756T3 (es) | Derivados de acido sulfonico utilizados en el tratamiento de enfermedades virales. | |
| ES2105913T3 (es) | Composiciones para el teñido de las fibras queratinicas que comprenden un orto-diamino pirazol y una sal de manganeso, procedimiento de teñido que utiliza estas composiciones. | |
| ES2152990T3 (es) | Principios activos y microparticulas que contienen gases. | |
| BRPI0414099A (pt) | impulsionador celular de faixa curta | |
| ES2153654T3 (es) | Vectores retrovirales. | |
| DK1347736T3 (da) | Oxiderende sammensætning til behandling af keratinstoffer på basis af amfifile polymerer med mindst en ethylenisk umættet monomer med en sulfonsyregruppe og som omfatter en hydrofob del | |
| GT200000200A (es) | Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad. | |
| ES2035384T3 (es) | Procedimiento para la esterilizacion de sangre, plasma, derivados de la sangre y del plasma, suspensiones celulares o similares. | |
| GT199900214A (es) | Combinacion de cerivastatina y fibratos. | |
| ES2076965T3 (es) | Activadores del plasminogeno salivares del murcielago vampiro. | |
| DK1702979T3 (da) | Improved keratinocyte culture and uses thereof | |
| ES2151908T3 (es) | Derivados del acido fenil-ciclohexano-carboxilico sustituidos con heterociclo. | |
| DE60229417D1 (de) | Setzungen auf basis von pyrogenisch hergestelltem siliziumdioxid | |
| ES2108228T3 (es) | Factor de diferenciacion de megacariocitos. | |
| NO20010843D0 (no) | Subtile mitokondrie mutasjoner som tumormarkører | |
| ES2090963T3 (es) | Higado biologico artificial. | |
| TR200000588U1 (tr) | Aerosol ilaçların ağızla içe solunmasında kullanılma amaçlı meme. | |
| ES2170798T3 (es) | Benzopiranos y su uso como agentes terapeuticos. | |
| ES2125873T3 (es) | Plasmido hibrido para el antigeno con 38 kda de m. tuberculosis, e. coli como hospedante, el antigeno con 38 kda y una proteina con aproximadamente 33kda. | |
| ES2130415T3 (es) | Linfocitos t tumoricidas. | |
| CR5757A (es) | Nuevo marcador de seleccion |